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Synthetic chemical drugs, while being eﬃcacious in the clinical management of many diseases, are often associated with
undesirable side eﬀects in patients. It is now clear that the need of therapeutic intervention in many clinical conditions cannot be
satisfactorily met by synthetic chemical drugs. Since the research and development of new chemical drugs remain time-consuming,
capital-intensive and risky, much eﬀort has been put in the search for alternative routes for drug discovery in China. This
narrative review illustrates various approaches to the research and drug discovery in Chinese herbal medicine. Although this article
focuses on Chinese traditional drugs, it is also conducive to the development of other traditional remedies and innovative drug
discovery.
1. Introduction
The process of chemical drug discovery is long and arduous
that it begins from the search of a potential candidate to the
development of a marketable drug. It can span the course
of more than a decade, and can cost an average of 800
million USD in the USA [1–3]. Under special circumstances
such as the search for eﬀective drugs to treat AIDS, the
Food and Drug Administration (FDA) in USA and other
countries have encouraged an abbreviated process for drug
testing and approval (called fast tracking) [4, 5]. However,
the rapid withdrawal of natalizumab used for the treatment
of relapsing multiple sclerosis has raised concerns over the
issue of commercial licensing [6]. Recently, the number of
drugs launched in the market did not increase. From 2006
to 2008, only 30–41 new drugs, including synthetic chemical
drugs and biopharmaceuticals as well as new diagnostic
agents, reached their first markets [7–9].
Chinese herbal medicine (CHM, Zhong-Yao), a pharma-
ceutical part of traditional Chinese medicine (TCM, Zhong-
Yi), has a long history of use, with extensive literature and
clinical applications covering thousands of years [10, 11].
It has been widely accepted that CHM has evolved over
the millennia, with a battery of herbal materials to preserve
health, to treat and prevent illnesses [12, 13]. Over the past
decades, CHM has been an area of intensive research aiming
at developing new drugs for the ever-evolving diseases aﬄict-
ing mankind [14]. Because the development of new chemical
drugs remains time consuming, capital-intensive and risky
(i.e. a low rate of success), much more eﬀort has been put
in CHM for drug discovery. At the present time, CHM has
been a novel basis of drug development in China. Up to 2007,
China has collected 3563 extracts, 64 715 compositions, and
5000 single compounds from 3000 Chinese herbs, together
with about 130 kinds of chemical drugs obtained from either
CHM ingredients or their derivatives [15]. In this article
we systematically summarized the contemporary approaches
and strategies of research and development (R&D) on CHM.
We also enthusiastically put forward our point of view on this
matter.
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2. Current Status on the CHM R&D
CHM is used by a large number of patients in China and
elsewhere in the world. Currently, CHM is available in both
traditional and modern forms of application. Based on some
successful experiences, approaches in CHM R&D can be
summarized in the following.
2.1. Reform of CHM Formulation. Dosage forms of Chinese
herbal formula commonly used in clinic include decoction
(Tang-Ji in Chinese), powder (San-Ji in Chinese), bolus
(Wan-Ji in Chinese), and paste (Jin-Gao in Chinese) and
so forth. It was said that Yi Yin, the minister of the Shang
Dynasty (1600–1046 BC), invented the decoction of CHM
[16]. The manufacture of CHM products has been improved
by contemporary pharmaceutical processes, wherein active
ingredients from herbs are extracted and concentrated,
which are then formulated into granules or easy-to-swallow
tablets and oral liquid, and even liquid dosage form for intra-
venous injection [17–19]. Up to now, China has produced
the modern CHM formulations 40 species, >8000 varieties
of CHM have been exported to more than 130 countries and
regions [20]. In addition, delivery systems for CHM have
recently undergone great improvement along with advances
in modern pharmaceutical technology. As such, CHM, like
Western medicine, can be delivered to specific target and/or
exists in controlled release formulation [21–23].
A good example is Xiao-Chai-Hu-Tang, which is com-
prised of Radix Bupleuri, Radix Scutellariae, Rhizome
Pinelliae, Radix Zingiber Oﬃcinale, Radix Ginseng, Fructus
Jujubae and Radix Glycyrrhizae. These herbal drugs are
manufactured and formulated into granules by advance
pharmaceutical processes in Japan, which can then satisfy the
consumers’ need and expectation for quality assurance [24–
26]. The manufacture of granule form of CHM is generally
described as follows. Raw herbal materials are cut into thin
pieces followed by the extraction with hot water. After the
filtration process, the water extract is concentrated in order
to enhance the stability of chemical ingredients. Finally, the
concentrated extract is granulated and packed [27]. However,
the price of the granulated form of CHM is twice that of the
raw herb, and therefore the former is unwelcome in some
poverty-stricken areas in China [28]. There are 51 kinds of
CHM granules recorded in The Chinese Pharmacopoeia 2005.
Granule forms of CHM (single herb or multi-component
formula) oﬀer many advantages over decoction in terms of
convenience in administration and eﬃciency in extraction.
The household process of decoction can extract 45% of active
ingredients from herbs through simmering [29]. Studies
indicated that the extraction eﬃciency by various methods
is in a descending order of pressurized liquid extraction
> sonication extraction > supercritical fluid extraction >
hydrodistillation and decoction [30]. As such, the traditional
way of making decoction of Chinese herbal formula should
be modified by using modern pharmaceutical processing
technology such as suspension freeze-concentration, pro-
gressive freeze-concentration, single- or multi-eﬀect evap-
oration with an external natural circulating flow, on-
line foul preventing evaporation with vapor-liquid-solid
flow, reverse osmosis concentration, membrane distillation,
osmotic distillation and macro-porous resin adsorption, and
so forth [31, 32]. Recently, nanotechnology has been utilized
to formulate herbal preparations into nano-sized granules
and thereby increases their eﬃcacy, presumably through
enhancing the bioavailability [33–35]. The utilization rate
of “nanomized CHM” may be achieved up to 95%, and
this makes economical sense for expensive CHM. “CHM
granules” or “nanomized CHM” are dissolved in hot water
and be consumed. The modernized dosage forms represent
a convenient and eﬀective way of taking CHM as compared
with herbal decoction.
2.2. Reform of CHM Formulae. In the practice of TCM,
multiple-herb formula is prescribed for patients. According
to the theory of TCM, component herbs in a formula
can somehow achieve synergistic therapeutic actions and/or
minimize the adverse reactions arising from some ingre-
dients [36]. TCM is an ancient medical practice which
uses diﬀerent treatment modalities, such as acupuncture,
Qi-Gong, food therapy, touch and massage therapy and
CHM therapy, for the prevention and treatment of diseases.
Ancient Chinese philosophical concepts on Yin-Yang and
Wu-Xing (five elements) form the basis of TCM theories.
CHM includes 11 146 kinds of medicinal plants, 1581 kinds
of animal drugs, 80 kinds of mineral drugs. There are also
more than 50 kinds of processed remedies and 5000 clinically
proven folk medicines [14].
In China, there are tens of thousands of herbal pre-
scriptions from CHM, including 84 464 traditional formulae
and 10 704 commonly used formulae [37, 38]. There are
also herbal formulae from other ethnical medicines such
as Dai medicine, Tibetan medicine, Yi medicine, Miao
medicine and Naxi medicine, and so forth. They are ready
for exploitation in drug discovery. Although TCM, the
mainstream of healthcare in China for several thousand
years, has accumulated lots of clinical experience, it was
developed in ancient time after all. The reform of traditional
herbal formulae is necessary in order to make them more
applicable to contemporary clinical conditions. For example,
Su-Xiao-Jiu-Xin-Wan, which is widely used in China for
angina pectoris, is comprised of eight components, including
toad venoms, bezoar, moschus, orpiment, borneol, pearl,
ginseng and antelope horn [39]. The original formula of Su-
Xiao-Jiu-Xin-Wan is Liu-Shen-Wan, consisting of six herbs,
namely, bezoar, moschus, toad venoms, orpiment, borneol
and pearl.
Nevertheless, the synergistic interactions between com-
ponent herbs are not always obvious. Su-Bing-Di-Wan,
comprising two herbs (styrax and borneol), is derived from
a parent formula Su-He-Xiang-Wan containing 15 herbal
components. However, both formulae displayed comparable
clinical eﬃcacy on coronary heart disease [40]. The use
of a simplified formula can certainly lower the drug cost,
reduce the rate of drug adverse reactions and conserve
Chinese herbal resources. In an herbal formula, the overall
eﬃcacy of two or more than two component herbs may not
always be more than additive, that is, >2. Sometimes, adverse
interactions may occur.
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2.3. CHM-Derived New Chemical Composition. The chemi-
cal composition of naturally grown herb may vary according
to climatic conditions, harvest time, storage condition, and
so on. As such, the same type of herb can vary in its com-
position and concentrations of chemical constituents from
batch to batch. These variabilities can result in significant
diﬀerences in pharmacological activity [41]. Therefore, the
identification and extraction of active ingredient(s)/chemical
group(s) from an herbal remedy represents a new approach
in the development of CHM. The herb-derived chemical
drugs, which have well defined pharmacodynamic and phar-
macokinetic profiles, are manufactured in pharmaceutical
grade with standardized chemical composition. One good
example is Ginkgo (Yı´n-Xı`ng in Chinese) leave extract
which contains 24% ginkgo-flavonol glycosides and 6%
terpene lactones [42]. At the present time, there are 15
major categories of active ingredients in CHM, including
flavones, alkaloids, glucides, glycosides, volatile oils, resins,
phytochromes, organic acids, amino acids, tannins, proteins,
enzymes, trace elements, polysaccharides and mineral salts.
Each phytochemical group contains thousands of single
compounds. For example, flavones contain more than 9000
derivatives/analogs of known structures, which produce anti-
cancer, anti-oxidant, anti-inflammatory, anti-bacterial, anti-
virus, anti-ischemic and anti-hypertensive actions [43, 44].
Inorganic salts present in CHM belong to 25 elements,
including Be, Cr, Cu, Zn, Ge, Sr, Mo, Cd, Tl and Pb, and so
forth [45].
In China, the pharmaceutical industry mainly focuses
on the exploration of active extracts rather than single
compound in the product development from CHM. A
pure compound isolated from an herb is regarded as
chemical drug (also known as Western medicine). While
water or ethanol extracts of herbs are too crude in terms of
chemical composition, preparations containing concentrated
phytochemical compounds are preferred to be used as
herbal drugs. For instance, Di’ao-Xin-Xue-Kang (Chinese),
a Chinese herbal formula used for the prevention and
treatment of coronary heart disease including angina, is
consisted of steroidal saponins from Dioscorea panthaica
Prain et Burkill and Dioscorea nipponica Makino [46–48].
Yu-Feng-Ning-Xin-Pian (Chinese), a formula used for the
treatment of hypertension, senile cerebrovascular disease and
angina pectoris, is consisted of total flavonoids (including
puerarin) derived from Radix Puerariae [49, 50].
2.4. CHM-Derived New Chemical Compound. Despite the
long history of use, many clinical proven Chinese herbal
formulae are lack of a well defined mechanism of action. It
may therefore be necessary to identify the active ingredient(s)
from an herbal extract for mechanistic investigations. Up till
now, many active ingredients have been isolated from com-
monly used CHM such as anti-HIV candidate leucovorin
and agaritine derivatives as well as anti-Alzheimer’s disease
and anti-inflammatory candidate GTS-21 [51, 52]. These
compounds may serve as potentially useful drug candidates
for development at a lower cost. In this regard, active herbal
ingredients, such as alkaloids, flavonoids, quercetin, terpene
and lignoids, have been shown to produce anti-HIV action
[53]. In addition, huperzine A, a novel alkaloid isolated
from Huperzia serrata, is clinically used for the treatment of
Alzheimer’s disease and vascular dementia [54]. Berberine,
an active ingredient from Coptis chinensis Franch, is widely
used for the treatment of infectious diseases in China [55].
Notably, arsenious acid derived from arsenic trioxide (Pi-
Shuang in Chinese) has become a first-line drug for the
treatment of acute promyelocytic leukemia [56, 57].
With the growing popularity of CHM for the prevention
and treatment of diseases, the ever-increasing demand for
Chinese medicinal plants has posed a threat to their extinc-
tion. The advent in medicinal plant cell culture technology,
which oﬀers an eﬀective alternative for supplying desirable
compounds in lieu of extraction from natural sources, comes
to the rescue. Active ingredients of ginseng, such as saponins
and polysaccharides, were obtained from cultured cells of
Panax ginseng to meet the need for mass production of these
bioactive ingredients [58, 59]. Plant cell and tissue culture
methods was introduced in the early 1960s, and commercial
applications have been underway since the late 1980s [60].
Paclitaxel (taxol) is an eﬀective anti-cancer agent found in
Taxus mairei. The plant is facing the threat of extinction
because of the great demand for wood and taxol production,
as well as the diﬃculty in its propagation. Fortunately, an
eﬀective cell culture technology for taxol production has
been established [61, 62]. In addition, the chiral property
or physical state (particularly for microelements) of the
active ingredient of an herb may be an important deter-
minant for its pharmacological and toxicological profiles
[63]. For instance, the nootropic action of (−)clausenamide
is 10- and 20-fold higher than those of (+)clausenamide
[64, 65].
2.5. Optimization of CHM-Derived Lead Compound. Active
ingredient(s) isolated from CHM can be produced by semi-
or total synthesis, with or without structural modification for
activity optimization. Given that designing a new chemical
entity from scratch is a daunting task, it is possible to
develop derivatives based on known molecular structures
from various herbal ingredients. In this respect, artemisinin,
a powerful anti-malarial drug with a rapid onset of action
and low toxicity, was extracted from Qing-Hao (Chinese)
in 1971 [66, 67]. At the present time, it is a key drug in
combination therapies recommended by the World Health
Organization (WHO) for the treatment of uncomplicated
multi-drug-resistant strains of Falciparum malaria. Dihy-
droartemisinin is a compound derived from artemisinin with
higher clinical eﬃcacy and safety than that of the parent
drug [68, 69]. In addition, other Qing-Hao-Su (Chinese)
derivatives have been shown to possess anti-parasitic and
anti-cancer properties [70]. In China, Qing-Hao for treating
malaria has begun in the fourth century [71]. Artemisin
derived from Qing-Hao shows once again that natural
products serve as an invaluable source of lead compounds
for sophisticated small molecule drugs [72].
In an eﬀort to develop novel anti-viral hepatitis agent,
a number of analogues of schisandrin C (dimethyl-4,4′-
dimethoxy-5,6,5′,6-dimethylene dioxybiphenyl-2,2′-dicarb-
oxylate), an active ingredient isolated from Wu-Wei-Zi
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(Chinese) were synthesized, including bifendate (dimet hyl-
4,4′- dimethoxy-5,6,5′6′-dimethylene-dioxybipheny1-2,2′-
dicarboxy late) and bicyclol (4,4′-dimethoxy-5,6,5′,6′-dime-
thylene-dioxy-2-hydroxymethyl-2′-carbonyl biphenyl) [73,
74]. These compounds, like Wu-Wei-Zi, have been shown
to protect the chemically induced hepatotoxicity in experi-
mental animals and to be eﬀective in treating patients with
chronic viral hepatitis as well as some other diseases [75–77].
2.6. Matching of CHM Ingredients and Molecular Targets of
Disease. In the past, most drugs were discovered either by
identifying the active ingredient(s) from traditional remedies
or by serendipity. A new approach for drug discovery involves
the elucidation of molecular mechanism(s) underlying
the disease/infection process followed by the identification
of drug target. Despite the advances in technology and
biomedical sciences, drug discovery is still a time-consuming
process, with a low rate of success. Recently, a search of active
ingredient(s) from 240 commonly used CHM in relation to
relevant drug targets in a database has revealed a wide variety
of compounds that have therapeutic potential. About 62% of
the species were found to contain chemical compounds with
pharmacological profile beneficial for the treatment of at
least one disease and 53% of them for two or more diseases.
Approximately 7000 unique compounds are listed, though
some are found in more than one herb, the total number for
all herbs being 8264. For bioactive plant compounds, 2597
compounds active against 78 molecular targets are covered
[78]. In comparison with the high-throughput screening
against a chosen target for a particular disease, virtual
mapping between databases of Chinese herbal ingredients
and molecular targets of diseases is likely to oﬀer a new
avenue for drug discovery [79–81].
2.7. CHM-CHM Interaction in Multi-Component Herbal
Formulae. The principle of formulation in TCM is adopted
to guide the choice of herbs (herb matching) in multi-
component herbal formulae prescribed for the treatment of
diseases. It is documented that 91% of the 6986 herbal for-
mulae are multi-component and 3196 herbal materials were
used to constitute 11 810 formulae [82]. As such, an optimal
therapeutic eﬀect can be achieved by herbal treatment.
While the theory underlying the principle of formulation
has yet to be clearly established in modern scientific terms,
two possible outcomes resulting from herbal interaction in
the mixture have been proposed: (i) synergistic interaction
among component herbs and (ii) generation of secondary
compound(s) from the decoction process. The significance
of herb matching has been revealed in a few formulations
including Six Ingredient Rehmannia Decoction (Liu-Wei-
Di-Huang-Wan) and Pulse Promoting Drink (Sheng-Mai-
Yin or its parent formula Shengmai San) [83, 84]. All of these
formulae produce a therapeutic action, including chemical
entity, which is distinct from that produced by a single
component herb [85].
Seeking new chemical entities in multi-component
herbal formulae is a promising approach in drug discovery.
Up to now, there is no successful example. Since the eﬀects
of Chinese herbal formulae are not simply the summation
of component herbs, one or more new compound(s) may be
produced from herb-herb interaction during the decoction
process. These new chemical compounds should be identi-
fied.
2.8. CHM Metabolites. Pharmacokinetics is a branch of
pharmacology specialized in the determination of the fate of
drugs following the administration into a living organism.
According to pharmacokinetics studies, administered drugs
may have their chemical structures altered after metabolism
and biological activities of the parent drugs are thus changed
[86, 87]. In this connection, the pharmacological/toxic
action of drugs may not be due to the drug itself, but to its
active metabolite(s) in the body. For instance, the half-life
of intravenously administered levosimendan, an inotropic
drug, is very short (∼1.5 h), but it can cause a prolonged
hemodynamic improvement in patients with heart failure
because of its long half-life active metabolite, OR-1896
[88, 89]. In addition, genotoxic metabolites of estradiol can
bind onto DNA and cause depurination, thereby developing
breast cancer in women [90].
Chinese herbal formulae are consisted of multiple herbs
and therefore are liable to produce a large number of
metabolites which may act on multiple targets in the
body. Availability of such a large number of metabolites
is likely to open up opportunities for drug discovery [91].
Pharmacological investigations on herbal formulae and
their metabolites may reveal the complexity of inter-organ
functional relationship, which is instrumental in defining the
therapeutic action of multi-component herbal remedies.
2.9. Integrative Drug. In China, CHM can be combined in
use with Western drug (i.e. chemical drug). In doing so,
Chinese herbal extract or active ingredient can be admixed
with Western drug. Despite the diﬀerence in the diagnostic
and treatment principle between Chinese medicine and
Western medicine, over the past 50 years, the integration of
these two medical systems in clinical settings has become
popular and achieved significant developments in China
[92]. This area of integrated medicine is referred to as
modern Chinese medicine (MCM). The “marriage” of
Chinese medicine and Western medicine has indeed brought
a lot of benefits to patients. In most clinical conditions, the
combination therapy with CHM and Western drugs provides
a greater therapeutic eﬀectiveness than using either herbal or
Western drug alone. One clinical condition in which MCM
is commonly applied is chronic hepatitis C. The MCM-
based treatment for hepatitis C is aimed to (i) control liver
inflammation and prevent fibrosis by Western drugs and (ii)
restore normal liver functions and overall health condition,
particularly the immune function, with herbal remedies [93].
Currently a large number of formulations containing
CHM and Western drug are available in China market. There
are 201 Chinese herbal preparations (internal medicine
175 kinds, topical medicine 58 kinds) admix with Western
drug(s) in The Chinese Pharmacopoeia 2000. On the other
hand, pure ingredient or its derivative in CHM is mixed with
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Figure 1: Approaches in R&D of CHM.
chemical drug. For example, artemether compound tablet
(Coartem), which is an anti-malarial agent consisting of
artemisinin derivative artemether and synthetic benflumetol
[94, 95].
2.10. Covalent Modification of CHM Compound with Chem-
ical Drug. Drug developed from MCM may involve the
direct structural linkage between Chinese herbal compound
and Western drug. For example, huperzine A, a naturally
occurring sesquiterpene alkaloid found in H. serrata, and
tacrine, a prototypical cholinesterase inhibitor, are cova-
lently linked to form a novel dimer, HA′(10)-tacrine [96,
97]. Experimental studies indicated that HA′(10)-tacrine
was eﬀective for improving cognitive deficits in several
animal models and caused a relatively low liver toxicity
[98, 99]. HA′(10)-tacrine may therefore be used for the
treatment of Alzheimer’s disease and other neurodegen-
erative disorders. In addition, two Chinese herbal com-
pounds can be linked to form a new drug. Tanshinol bor-
neol ester (1,7,7-trimethylbicyclo [2.2.1] heptan-2-yl-3-(3,4-
dihydroxyphenyl)-2-hydroxy-propanoate), a novel com-
pound synthesized by linking tanshinol and borneol ester,
is prescribed for the treatment of cardio-cerebrovascular
diseases [100].
Despite the modernization process, the practice of TCM
should still be based on the holistic concept of integrated
body systems that work in balance to maintain the healthy
body condition. With such a mind set in place, drug
discovery from CHM should be focused on compounds or
extracts that can act on multiple targets in the body. In view
of the current technological support and market sentiment,
some of the aforementioned approaches should be feasible
for drug discovery (Figure 1).
3. Discussion
At the present time, many people are interested in CHM
including other nature remedy and alternative therapy [101],
with an attempt to explore its commercial potential. In doing
so, we should note the following points.
3.1. An Herbal Remedy Cannot Be Substituted by a Sin-
gle Compound. Three reasons are likely underlying the
increasing popularity of herbs. First, modern medicine has
failed to oﬀer a complete cure for many diseases. Secondly,
patients are turning to herbs in dealing with symptoms
or side eﬀects resulting from chemical drug treatments.
Thirdly, people utilize herbs to improve the overall well-
being and health or to prevent diseases. With the mind
set of modern medicine, once the eﬃcacy of an herb is
validated by scientific investigations, scientists will attempt
to substitute the herb with its active extract or ingredient.
For example, morphine, a naturally occurring compound
extracted from Asian opium poppy plant, is not only a very
potent analgesic but also a highly addictive drug. In this
regard, scientists have attempted to eliminate its addictive
property and at the same time, retain its analgesic action
through modifying the chemical structure of morphine. As a
result, heroin (diamorphine) was made. Methamphetamine
hydrochloride (ice, Bing-Du in Chinese) is a product from
the structural reformation of ephedrine, an alkaloid found
in a CHM, Ephedra sinensis. Unfortunately, while drug
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addicts over the world amount to 25 million, the market
for methamphetamines and amphetamines continues to be
larger than that for cocaine (14 million users) or heroin (11
million users) [102].
While isolating or concentrating an active ingredient
from an herb can markedly enhance its therapeutic potency
on a specific aspect, as compared to the use of crude
herb, herbal extract, or herbal decoction, it may also lead
to undesirable side-eﬀect(s) due to the unbalanced mode
of action. The so called “herbal medicine” that uses the
active ingredient isolated from an herb or synthesized by
chemical processes is not much diﬀerent from a chemical
drug. After all, a single active ingredient from an herb should
be regarded as a chemical drug in modern medicine and
will be examined according to the Western pharmaceutical
compound standard. Therefore, the drug discovery from
herbs, particularly CHM, should focus on multi-component
herbal formulae (Fang-Ji in Chinese), with emphasis on
the herb-herb interaction in producing a therapeutic eﬀect.
The FDA recognizes CHM as medicinal products containing
active ingredients of exclusively plant origin without well-
defined active ingredients [27].
In addition, the active single compound is often uniden-
tifiable and its isolation or extraction is also diﬃcult.
Furthermore the combination and matching of more than
two herbs in CHM is considered more useful than using
a single one. In fact, combination therapy in Western
medicine (chemical drug) is also a common practiced in
clinical situation such as cocktail therapy in AIDS [103]
and combination medication in patients with hypertension
[104]. Like chemical drug, there are additive, synergic,
antagonistic, inhibitory, destructive and opposite action
among herbs or their ingredients. Under the guidance of
TCM theory, the combination of herbs would enhance the
eﬃcacy and minimize the adverse reaction of CHM. More
importantly, pure compound derived from CHM might
lose the original properties of the remedy. Unlike Western
medicine, the application of CHM prescriptions (formulas)
is guided by herbal properties (Yao-Xing in Chinese) and
symptoms/signs of patients (Zheng-Hou in Chinese) rather
than a well-defined drug target [105, 106].
3.2. New Applications of Traditional Herbal Remedy. Since
ancient time, plants have been employed as the source of
medicine in all cultures. The new use of old herbs, as were the
cases for many chemical drugs, is important for introducing
new applications for traditional herbs. For instance, Fructus
Schisandrae (FS), the fruit of Wu-Wei-Zi, is regarded as a
tonic agent in CHM. FS has been used for thousands of
years in China. A large number of pharmacological and
clinical studies have shown that FS produces a systemic
eﬀect in the body [107]. In our laboratory, an ethanol
extract of FS [108], its active ingredient schisandrin B
[109], as well as its related synthetic derivatives bifendate
[110] and bicyclol [111] have been shown to suppress the
lipid accumulation in the liver, but without aﬀecting serum
lipid levels, in experimental hypercholesterolemic mice. The
possible clinical use of FS for the clinical management of fatty
liver disease exemplifies the new use of an old herb in CHM.
In addition to antimicrobial activity, berberine, an alkaloid
present in C. chinensis Franch., has been found to possess
hypoglycemic and hypocholesterolemic activities as well as
other pharmacological properties [112–114].
In addition, veterinary drugs, diagnostic/pharmacolog-
ical agents for the research in life sciences, and food additives
may be developed from herbal remedy. These are often
cheaper and easier to develop than new therapeutic agent or
compound. Recently, for example, Pan et al. have established
an animal model of hypertriglyceridemia using schisandrin
B isolated from Fructus Schisandrae and its related synthetic
analog bifendate [115, 116].
3.3. New Source of Herbal Ingredients. Herbs are derived from
plant materials such as leaves, flowers, fruit, seed, stems,
wood, bark, roots, rhizomes or other plant parts. Given that
the therapeutic eﬀect of an herb depends on the ingredients
present in the plant part, if the bioactive substance is also
present in other plant parts or even the whole plants, it
can be exploited. Ginsenosides, which encompasses more
than 40 kinds of monomeric compounds, are major active
ingredients of Radix Ginseng (the root part of P. ginseng)
with a wide spectrum of pharmacological actions [117, 118].
In fact, ginsenosides were also found in the leaves and stems
of P. ginseng [119, 120]. It is likely that leaves and stems of
P. ginseng can produce similar pharmacological actions as
Radix Ginseng.
For example, tea-drinking is invented by Chinese about
4700 years ago. Saichyo (767–822 AD), a Japanese who
studied in China, was the first man bringing tea-drinking to
Japan. In 1610, Dutch merchants transported tea from China
to Europe [121]. Tea-drinking has been regarded as a health-
promoting habit in the world [122–124]. Many plant species
other than Camellia sinensis have been used for tea leaves.
In addition, tea flower is used as food in Japan [125] and oil
extracted from tea seeds is used as cooking oil in China [126].
3.4. Highlight the Advantages of CHM. In fact, comple-
mentary and alternative medicine (CAM) involves drug
therapy (pharmaceutical CAM) and non-drug therapy (non-
pharmaceutical CAM). Drugs employed by all CAM are
herbs including spices and vegetables. Herbal medicine
worldwide can be classified into four basic systems, namely,
Chinese herbalism, Ayurvedic herbalism [127–129], Western
herbalism and Arabic/Islamic herbalism [130, 131]. Western
herbal medicine, which was originated from Greece and
Rome, had been spread from Europe to North and South
America. However CHM is of more multiplicity than other
CAM. They include herbs (90%), animal parts, minerals
and crude synthetics. When compared with other traditional
herbal medicines elsewhere in the world, CHM has been
endowed with a more complete set of theories and thera-
peutic principles from TCM for guiding diﬀerent treatment
modalities in a variety of clinical conditions. Unlike some
other traditional medicines, TCM is not attached to any
religions or superstitious beliefs. Given the less sophisticated
way of making diagnosis and treatment, the practice of TCM,
with the use of CHM for treatment, is much less costly than
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modern medicine for patients. Cost-eﬀective choice in the
treatment of disease is important for patients, physicians and
policy makers under the times of economic crisis [132]. It
is not unusual for TCM practitioners to succeed in treating
diﬃcult clinical conditions that modern medicine has failed.
There are many diﬀerences between TCM and Western
medicine. The prescription of Chinese herbal formula as a
treatment modality for diverse medical conditions is based
on the diﬀerentiation of symptoms and signs, also known
as Bian-Zheng in Chinese [12, 133]. According to TCM
theory, patients can be categorized into eight groups: Yin or
Yang, Biao or Li (superficial or internal), Han or Re (cold or
hot), Xu or Shi (deficient or replete). All these disease states
may or may not be paralleled by counterparts in Western
medicine. Medicinal property of CHM is divided into Si-Qi
(four properties) such as cold, cool, warm and hot and Wu-
Wei (five tastes) such as pungent, sour, sweet, bitter and salty.
The application of CHM in clinical condition is based on the
diagnosis derived from Bian-Zheng and medicinal properties
of CHM, with the therapeutic aim of re-adjusting the body
to a normal condition from a disease state, rather than just
treating disease [134].
The practice of TCM is mainly based on an empirical
approach which has yet to be accepted in Western medicine.
Despite the long history of use, the therapeutic application
of CHM or their formulae needs to be validated by experi-
mental and/or clinical evidence obtained from contemporary
studies using appropriate methodologies. After all, the
eﬃcacy and toxicity of CHM need to be addressed by
scientifically acceptable language in the 21st century. Herbal
interaction among component herbs in a formula should be
analyzed and revealed. In view of these, the CHM R&D is
certainly a challenging task.
It is true that most Chinese herbal preparations do not
look as pleasant or good in appearance or taste as modern
chemical drugs, and their action mechanisms and dosages are
not defined in a precise manner. However, with appropriate
applications, CHM can work as good as chemical drugs,
but with considerably fewer serious adverse eﬀects. CHM is
a wealth of naturally occurring bioactive agents. This has,
in turn, provided a golden opportunity for drug discovery
in CHM. With all “natural forces” at work, the nature will
provide a plentiful of exploitable resources for maintaining
life activities. Defense against diseases are readily available in
the form of naturally occurring chemicals or substances such
as CHM.
4. Conclusion
Initially driven by chemistry and increasingly guided by
pharmacology and clinical sciences, drug research has con-
tributed more than any other scientific factors to the progress
of medicine during the past century. Although modern
pharmaceutical science has achieved tremendous success in
treatment of diseases, including those being regarded as
incurable for decades, a considerable number of diseases
still remain incurable by chemical drugs. Herbal medicine,
particularly CHM, has a traditional history of use, being
rooted in the cultural heritage of diﬀerent ethnic groups. To
demonstrate that herbs produce as much beneficial eﬀect as
modern medicine by scientific means remains a challenge,
particularly when using criteria applied for assessing chemi-
cal drugs which are consumed in a purified and concentrated
form [135]. Nevertheless, we firmly believe that CHM, with
its long history of use and detailed documentation in both
theory and practice, will play an important role in new drug
discovery in the future. As the theory of TCM goes, we
should count on our body defense mechanism for fending oﬀ
diseases. That means “treat before getting sick”. In this regard,
many CHM can be used for up-regulating the functioning of
antioxidant and immune systems in the body. If researches
on CHM-derived drug are conducted using contemporary
methodologies and biomarkers, they will produce great
impact on the mainstream biomedical science and likely
bring about an era of modern medicine [136, 137].
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